FYN and cancer: Tintori et al. identified by a virtual screening three micromolar ATP-competitive FYN inhibitors (38–40, Table 2) as promising hit compounds for both tauopathies and cancer treatment (Ki = 2.1, 2.25 and 0.9 μM, respectively).